CeriBell (NASDAQ:CBLL - Get Free Report) has received a consensus rating of "Buy" from the seven analysts that are currently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $32.50.
CBLL has been the subject of a number of research reports. TD Cowen boosted their price target on shares of CeriBell from $31.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, December 9th. LADENBURG THALM/SH SH started coverage on CeriBell in a research report on Friday. They issued a "buy" rating and a $32.00 target price for the company. Finally, Canaccord Genuity Group restated a "buy" rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th.
View Our Latest Report on CBLL
CeriBell Price Performance
NASDAQ CBLL traded down $0.20 during trading on Friday, reaching $17.99. 37,351 shares of the company's stock were exchanged, compared to its average volume of 236,616. CeriBell has a 1 year low of $17.24 and a 1 year high of $32.75. The stock has a 50 day simple moving average of $21.86.
CeriBell (NASDAQ:CBLL - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. As a group, equities research analysts expect that CeriBell will post -2.46 earnings per share for the current year.
Hedge Funds Weigh In On CeriBell
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc acquired a new stake in CeriBell during the 4th quarter worth approximately $32,000. Summit Investment Advisors Inc. acquired a new position in CeriBell in the 4th quarter valued at $33,000. Tower Research Capital LLC TRC purchased a new position in CeriBell during the 4th quarter worth $37,000. BNP Paribas Financial Markets purchased a new position in CeriBell during the 4th quarter worth $43,000. Finally, PNC Financial Services Group Inc. acquired a new stake in shares of CeriBell in the 4th quarter worth $47,000.
About CeriBell
(
Get Free ReportWe are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Featured Articles
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
